Literature DB >> 27714575

AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.

Kailash Prasad1, Indu Dhar2, Qifeng Zhou3, Hamdi Elmoselhi3, Muhammad Shoker2, Ahmed Shoker3.   

Abstract

Interaction of advanced glycation end products (AGEs) with its cell-bound receptor (RAGE) results in cell dysfunction through activation of nuclear factor kappa-B, increase in expression and release of inflammatory cytokines, and generation of oxygen radicals. Circulating soluble receptors, soluble receptor (sRAGE), endogenous secretory receptor (esRAGE) and cleaved receptor (cRGAE) act as decoy for RAGE ligands and thus have cytoprotective effects. Low levels of sRAGE and esRAGE have been proposed as biomarkers for many diseases. However sRAGE and esRAGE levels are elevated in diabetes and chronic renal diseases and still tissue injury occurs. It is possible that increases in levels of AGEs are greater than increases in the levels of soluble receptors in these two diseases. Some new parameters have to be used which could be an universal biomarkers for cell dysfunction. It is hypothesized that increases in serum levels of AGEs are greater than the increases in the soluble receptors, and that the levels of AGEs is correlated with soluble receptors and that the ratios of AGEs/sRAGE, AGEs/esRAGE and AGEs/cRAGE are elevated in patients with end-stage renal disease (ESRD) and would serve as an universal risk marker for ESRD. The study subject comprised of 88 patients with ESRD and 20 healthy controls. AGEs, sRAGE and esRAGE were measured using commercially available enzyme linked immune assay kits. cRAGE was calculated by subtracting esRAGE from sRAGE. The data show that the serum levels of AGEs, sRAGE, cRAGE are elevated and that the elevation of AGEs was greater than those of soluble receptors. The ratios of AGEs/sRAGE, AGEs/esRAGE and AGEs/cRAGE were elevated and the elevation was similar in AGEs/sRAGE and AGEs/cRAGE but greater than AGEs/esRAGE. The sensitivity, specificity, accuracy, and positive and negative predictive value of AGEs/sRAGE and AGEs/cRAGE were 86.36 and 84.88 %, 86.36 and 80.95 %, 0.98 and 0.905, 96.2 and 94.8 %, and 61.29 and 56.67 % respectively. There was a positive correlation of sRAGE with esRAGE and cRAGE, and AGEs with esRAGE; and negative correlation between sRAGE and AGEs/sRAGE, esRAGE and AGES/esRAGE, and cRAGE and AGES/cRAGE. In conclusion, AGEs/sRAGE, AGEs/cRAGE and AGEs/esRAGE may serve as universal risk biomarkers for ESRD and that AGEs/sRAGE and AGEs/cRAGE are better risk biomarkers than AGEs/esRAGE.

Entities:  

Keywords:  AGEs/sRAGE; Advanced glycation end products (AGEs); End-stage renal disease; Inflammation; Soluble receptors for AGE; cRAGE; esRAGE; sRAGE

Mesh:

Substances:

Year:  2016        PMID: 27714575     DOI: 10.1007/s11010-016-2829-4

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  35 in total

1.  Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.

Authors:  Sho-ichi Yamagishi; Hisashi Adachi; Kazuo Nakamura; Takanori Matsui; Yuko Jinnouchi; Katsuhiko Takenaka; Masayoshi Takeuchi; Mika Enomoto; Kumiko Furuki; Asuka Hino; Yoshiyuki Shigeto; Tsutomu Imaizumi
Journal:  Metabolism       Date:  2006-09       Impact factor: 8.694

2.  Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients.

Authors:  K Taki; F Takayama; Y Tsuruta; T Niwa
Journal:  Kidney Int       Date:  2006-05-24       Impact factor: 10.612

3.  Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients.

Authors:  Erick D McNair; Calvin R Wells; A Mabood Qureshi; Rashpal S Basran; Colin Pearce; Jason Orvold; Jacobus Devilliers; Kailash Prasad
Journal:  Int J Angiol       Date:  2009

4.  Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia.

Authors:  Enzo Emanuele; Angela D'Angelo; Carmine Tomaino; Giuliano Binetti; Roberta Ghidoni; Pierluigi Politi; Livia Bernardi; Raffaele Maletta; Amalia C Bruni; Diego Geroldi
Journal:  Arch Neurol       Date:  2005-11

5.  Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.

Authors:  Colomba Falcone; Enzo Emanuele; Angela D'Angelo; Maria P Buzzi; Chiara Belvito; Mariaclara Cuccia; Diego Geroldi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-02-24       Impact factor: 8.311

6.  Advanced glycation end products (AGEs) and its receptors in the pathogenesis of hyperthyroidism.

Authors:  Gudrun Caspar-Bell; Indu Dhar; Kailash Prasad
Journal:  Mol Cell Biochem       Date:  2016-02-19       Impact factor: 3.396

7.  Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease.

Authors:  B K Kilhovd; T J Berg; K I Birkeland; P Thorsby; K F Hanssen
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

Review 8.  Advanced glycation end products: a Nephrologist's perspective.

Authors:  D S Raj; D Choudhury; T C Welbourne; M Levi
Journal:  Am J Kidney Dis       Date:  2000-03       Impact factor: 8.860

Review 9.  Soluble forms of RAGE in human diseases: clinical and therapeutical implications.

Authors:  Francesca Santilli; Natale Vazzana; Loredana G Bucciarelli; Giovanni Davì
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

10.  Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease.

Authors:  Giuseppina Basta; Daniela Leonardis; Francesca Mallamaci; Sebastiano Cutrupi; Patrizia Pizzini; Lorena Gaetano; Rocco Tripepi; Giovanni Tripepi; Raffaele De Caterina; Carmine Zoccali
Journal:  Kidney Int       Date:  2009-11-18       Impact factor: 10.612

View more
  16 in total

1.  AGE-RAGE Stress in the Pathophysiology of Atrial Fibrillation and Its Treatment.

Authors:  Kailash Prasad
Journal:  Int J Angiol       Date:  2019-12-09

2.  [Mechanism of Shenbing decoction Ⅲ in the treatment of proteinuria in chronic kidney disease: a network pharmacology-based study].

Authors:  Huaxi Liu; Zhihao Lü; Chunyang Tian; Wenkun Ouyang; Yifan Xiong; Yanting You; Liqian Chen; Yijian Deng; Xiaoshan Zhao; Xiaomin Sun
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-02-28

Review 3.  AGE-RAGE Stress, Stressors, and Antistressors in Health and Disease.

Authors:  Kailash Prasad; Manish Mishra
Journal:  Int J Angiol       Date:  2017-12-28

Review 4.  Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?

Authors:  Kailash Prasad; Manish Mishra
Journal:  Int J Angiol       Date:  2017-02-03

Review 5.  Does AGE-RAGE Stress Play a Role in the Development of Coronary Artery Disease in Obesity?

Authors:  Kailash Prasad; Amal S Khan; Kalpana K Bhanumathy
Journal:  Int J Angiol       Date:  2022-02-12

6.  Investigating the Molecular Mechanism of Quercetin Protecting against Podocyte Injury to Attenuate Diabetic Nephropathy through Network Pharmacology, MicroarrayData Analysis, and Molecular Docking.

Authors:  Xiaoqin Ma; Chenxia Hao; Meixiang Yu; Zhaokang Zhang; Jingjing Huang; Wanhua Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-16       Impact factor: 2.650

7.  Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study.

Authors:  Jacopo Sabbatinelli; Stefania Castiglione; Federica Macrì; Angelica Giuliani; Deborah Ramini; Maria Cristina Vinci; Elena Tortato; Anna Rita Bonfigli; Fabiola Olivieri; Angela Raucci
Journal:  Cardiovasc Diabetol       Date:  2022-06-06       Impact factor: 8.949

Review 8.  AGE-RAGE Stress and Coronary Artery Disease.

Authors:  Kailash Prasad
Journal:  Int J Angiol       Date:  2021-01-21

9.  The ratio of AGE to sRAGE independently associated with albuminuria in hypertensive patients.

Authors:  Kuang-Hsing Chiang; Jaw-Wen Chen; Shao-Sung Huang; Hsin-Bang Leu; Shing-Jong Lin; Po-Hsun Huang
Journal:  BMC Endocr Disord       Date:  2018-11-13       Impact factor: 2.763

10.  Role of the Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Prognostic Factor for Mortality in Hemodialysis and Peritoneal Dialysis Patients.

Authors:  Elena Dozio; Federico Ambrogi; Massimo de Cal; Elena Vianello; Claudio Ronco; Massimiliano M Corsi Romanelli
Journal:  Mediators Inflamm       Date:  2018-10-15       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.